August 27, 2024
$63.3 million of Net Revenue Q2 2024 +25.7% net revenue Comparable Growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs Q2 2023 Adjusted EBITDA of $6.3 million, up +64.5% vs Q2 2023 NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global
May 30, 2024
WHITE PLAINS, N.Y., May 30, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that the Company will participate in upcoming investor conferences. On June 5, 2024, the Company will participate in
May 21, 2024
$68.3 million of Net Revenue +21.0% Comparable Net Revenue: +20.6% Obagi Skincare and +21.5% Milk Makeup Adjusted EBITDA of $11.4 million, up +12.9% vs Q1 2023 WHITE PLAINS, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand
May 1, 2024
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or “the Company”), a global multi-brand beauty and wellness platform, today announced its participation in the CreatorIQ Connect Europe conference, which will be held in London on Thursday, May 2, 2024.
April 30, 2024
2023 Net Revenue of $218.1 million Group Combined Comparable Revenue of $212.5 million, a 15.3% increase vs 2022 Group Combined Adjusted EBITDA of $24.4 million, up from ($8.8) million in 2022 WHITE PLAINS, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the
Displaying 1 - 10 of 19
Print Page
Investor FAQs
RSS Feeds
Email Alerts
Contact IR